Cantor Fitzgerald Reiterates Overweight on Soleno Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a price target of $67.
July 31, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a price target of $67. This positive analyst rating and high price target could boost investor confidence in the short term.
The reiteration of an Overweight rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100